clinical trial · NCT05537571
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Cardiovascular DiseasesAtherosclerosisLipoprotein(a)SLN360Placebo
brief summary
Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events
started
Dec 13, 2022
primary completion
Jan 11, 2024
completion
Jul 1, 2024
last updated
Jul 1, 2025
official title
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol